Edgen Stock·Dec 09 2025, 02:43Back
Kymera Stock Jumps 46% on Drug Data
Edgen Stock·Dec 09 2025, 02:43
[1] ReAlta Announces Promising Phase 2 Data Demonstrating Rapid Clinical Responses and Target Engagement in Steroid-Refractory Acute GvHD at the ASH 2025 Annual Meeting - BioSpace (https://www.biospace.com/press-releases/realt ...)[2] Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025 - BioSpace (https://www.biospace.com/press-releases/kites ...)[3] CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting – Company Announcement - Financial Times (https://markets.ft.com/data/announce/detail?d ...)
